Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Overview of Artelo Biosciences Inc (ARTL)
Artelo Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. With a strong focus on lipid-signaling pathways and the endocannabinoid system, the company employs a disciplined approach to leverage decades of research and cutting‐edge science. Its innovative platform is designed to modulate complex biochemical networks, aiming to address significant unmet medical needs in conditions such as cancer, pain, anxiety, anorexia, and inflammation.
Core Business and Product Portfolio
At its core, Artelo Biosciences targets lipid-mediated signaling mechanisms to develop proprietary therapies that have the potential to transform patient care. The company’s research spans several therapeutic areas, including:
- Cannabinoid-based Therapeutics: Utilizing a proprietary cocrystal composition that combines cannabidiol (CBD) with tetramethylpyrazine (TMP), the company is innovating in the realm of cannabinoid pharmacology. Their flagship product candidate exhibits superior pharmacokinetic and pharmacodynamic properties compared to conventional CBD formulations.
- FABP Inhibitors: A highlight of the portfolio is the selective inhibition of Fatty Acid Binding Protein 5 (FABP5), an approach designed to provide non-opioid, non-steroidal pain management solutions. These inhibitors are being explored in various pain models including chemotherapy-induced peripheral neuropathy, cancer bone pain, and osteoarthritis-related discomfort.
- Appetite and Cachexia Management: Artelo is developing therapies aimed at supporting patients suffering from cancer-related anorexia. Their efforts focus on improving body weight, appetite, and overall quality of life by targeting specific G-Protein Coupled Receptors (GPCRs) linked to metabolic regulation.
Scientific Innovation and Research Excellence
Artelo Biosciences emphasizes scientific innovation and regulatory discipline. The company strategically leverages world-class research expertise in its collaborations across Europe and North America. This collaborative approach ensures that the preclinical and clinical development of their compounds is built on robust scientific findings. Utilizing advanced drug formulation techniques such as cocrystallization, the company addresses challenges related to solubility and bioavailability, thereby optimizing the delivery and efficacy of their compounds.
Operational Footprint and Global Presence
Headquartered in San Diego, California, and with a significant presence in Dublin, Ireland, Artelo Biosciences has strategically positioned itself at the nexus of global biopharmaceutical innovation. This dual presence facilitates access to premier research institutions and allows the company to foster partnerships with leading academic and commercial entities across both the North American and European markets.
Competitive Position and Industry Significance
In the competitive landscape of clinical-stage biopharmaceutical companies, Artelo Biosciences distinguishes itself through its specialized focus on lipid-signaling and endocannabinoid modulation. By capitalizing on novel mechanisms of action and proprietary technologies, the company aims to fill clinical gaps where existing therapies are inadequate. Its methodical approach to product candidate development, emphasizing improved pharmacological profiles and optimized formulations, positions it as a credible player in the market. In a world where precision medicine and targeted therapies are increasingly important, Artelo’s platform presents a relevant and enduring solution for diverse therapeutic challenges.
Expertise, Experience, and Collaborative Strength
The leadership at Artelo Biosciences is composed of experienced biopharmaceutical executives and renowned researchers with deep domain expertise. This seasoned team guides the company’s multi-disciplinary projects, ensuring that every phase of development integrates regulatory excellence and scientific rigor. Strategic collaborations with academic institutions and industry partners enhance the company’s pipeline by providing access to innovative methodologies and specialized research tools, thus reinforcing its commitment to high-impact therapeutic discoveries.
Research and Development Strategy
Artelo’s R&D strategy is driven by an integrated approach that spans early discovery to clinical development. Each product candidate is supported by extensive preclinical validation, demonstrating efficacy in well-established laboratory models of disease. The company’s emphasis on establishing patent-protected products further underscores its commitment to long-term innovation. Through an agile development process, Artelo continuously refines its drug candidates to enhance safety, dosing precision, and clinical applicability. This systematic approach highlights the company’s regulatory discipline and forward-thinking in addressing complex pathologies.
Addressing Unmet Medical Needs
The challenges in treating conditions such as chemotherapeutic pain, chronic neuropathies, and cancer-associated cachexia underscore a significant need for innovative therapeutic options. Artelo Biosciences’ approach, which modulates upstream lipid-signaling pathways, offers the potential to achieve clinical benefits not attainable with traditional therapies. By focusing on molecular targets that regulate bioactive lipids, the company promises solutions that are less reliant on conventional mechanisms, thereby reducing adverse effects while improving efficacy.
Scientific Integrity and Transparency
In its commitment to scientific integrity and transparency, Artelo Biosciences provides comprehensive disclosure on its research methods and collaborative engagements. The company’s numerous presentations at global scientific symposia demonstrate its dedication to contributing to the broader body of knowledge in cannabinoid research and lipid signaling. This openness reinforces its reputation for expertise and builds trust among stakeholders, including investors, researchers, and clinical practitioners.
Conclusion
Artelo Biosciences Inc is a dynamic and forward-thinking biopharmaceutical company that has built a niche in the development of novel therapies targeting lipid-signaling pathways. With a robust and diversified drug pipeline, a strong scientific foundation, and a global operational footprint, the company continues to contribute valuable insights and therapeutic solutions in areas where patient needs are greatest. By maintaining a clear focus on rigorous research and strategic collaborations, Artelo is well-equipped to sustain its relevance and impact in the evolving landscape of biopharmaceutical innovation.
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the Sequire Biotechnology Conference on February 2, 2023, at 1:00 PM ET. The presentation will focus on the Company’s ongoing Cancer Appetite Recovery Study (CAReS). The biotechnology sector is projected to reach $727 billion by 2025, highlighting its growth potential. This event, hosted virtually, aims to connect public biotech companies with investors. Artelo is dedicated to developing innovative treatments targeting significant unmet needs related to cancer and other conditions. More details can be found at artelobio.com.
Artelo Biosciences (Nasdaq: ARTL) reported financial results for the quarter ending September 30, 2022, showing a net loss of approximately $2.3 million, or $0.82 per share, compared to a loss of $2.2 million or $1.37 per share for the same period in 2021. As of September 30, 2022, the company had $19.5 million in cash and investments, expected to support operations through mid-2024. Enrollment for the Phase 2a Cancer Appetite Recovery Study (CAReS) is set to begin near year-end, following positive Phase 1b results.
Artelo also highlighted promising non-clinical data for its FABP5 platform, indicating potential treatments for both pain and anxiety.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29, 2022, in New York City. CEO Gregory D. Gorgas will speak at 8:30 a.m. ET, and one-on-one meetings will be available throughout the event. The presentation will also be streamed online. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathways, aiming to address significant unmet medical needs.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The event includes virtual and in-person attendance at the Lotte New York Palace Hotel. The presentation will be available on-demand starting September 12 at 7:00 AM ET. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathway modulation.
Artelo Biosciences (ARTL) recently announced pre-clinical findings suggesting that its fatty acid binding protein 5 (FABP5) inhibitor may effectively reduce anxiety behaviors in key brain areas. These results indicate that FABP5 modulation could serve as a new target for developing anxiety treatments, including potential therapies for post-traumatic stress disorder (PTSD). Published in Cerebral Cortex, the study led by researchers from the University of Western Ontario demonstrates the role of the CB2 receptor in managing fear and anxiety, underscoring the importance of this research.
Artelo Biosciences (Nasdaq: ARTL) announced advancements in its clinical programs with the CAReS Study for ART27.13, targeting cancer-related anorexia, progressing to a fourth cohort due to its well-tolerated safety profile. The company also reported a net loss of $2.4 million for Q2 2022 and a cash balance of $21.3 million, expected to fund operations into 2023. A 15-for-1 reverse stock split will take effect on August 10, 2022, aimed at enhancing stock marketability and compliance with Nasdaq requirements.
Artelo Biosciences (Nasdaq: ARTL) has initiated the fourth cohort at a 650-microgram dose in its Cancer Appetite Recovery Study (CAReS) for ART27.13, following successful completion of the first three cohorts. The safety review committee reported that ART27.13 was well-tolerated, with no serious adverse events linked to the drug. The Phase 1b trial will help determine the optimal dose before transitioning to a Phase 2a study. ART27.13 targets cannabinoid receptors to address cancer-related anorexia, tapping into a market exceeding $2 billion annually.
Artelo Biosciences (Nasdaq: ARTL) recently presented research at the ICRS Symposium highlighting the effectiveness of its lead compound, ART26.12, in managing chemotherapy-induced pain. Professor Saoirse O’Sullivan reported that ART26.12 demonstrated significant effectiveness in preventing and treating pain sensitivity without sedation, while also mitigating weight loss linked to chemotherapy. The company aims to pursue FDA consultations for ART26.12’s further development. This research opens potential pathways for addressing Chemotherapy-Induced Peripheral Neuropathy, a condition without approved therapies.
Artelo Biosciences (Nasdaq: ARTL) announced that Professor Saoirse O’Sullivan will present pre-clinical data on ART26.12, a fatty acid binding protein 5 inhibitor, at the International Cannabinoid Research Society Symposium on June 26, 2022. Gregory D. Gorgas, the company's CEO, expressed enthusiasm about sharing findings related to advancements in cancer treatment. Additionally, the William A. Devane Young Investigator of the Year Award will be presented at the event, recognizing significant contributions to cannabinoid research.
Artelo Biosciences (NASDAQ: ARTL) announced that CEO Gregory D. Gorgas will present at the LD Micro conference on June 7, 2022, at 2:30 PM PT. The event, held at Four Seasons Westlake Village, California, will feature live webcasting and replays available on their site. Artelo specializes in developing therapeutics targeting lipid-signaling pathways, addressing conditions like anorexia, cancer, PTSD, pain, and inflammation. The company emphasizes collaboration with experts and a focus on high-impact therapies.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What is the primary focus of Artelo Biosciences?
What types of therapies is Artelo developing?
How does Artelo Biosciences differentiate itself in the biopharmaceutical industry?
Where is Artelo Biosciences headquartered?
What is the significance of the company’s proprietary cocrystal technology?
What conditions are targeted by Artelo’s FABP inhibitors?
How does Artelo Biosciences support its research and development efforts?
Is Artelo focused on addressing unmet medical needs?
